Randomized Phase III Study on Bortezomib and Low-Dose Dexamethasone with or without Continous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma
(Multiples Myelom, Plasmozytom, Morbus Kahler, Knochenmarktumor,Non-Hodgkin-Lymphom, NHL, Plasmazellen, blutbildendes System, hämatologische Erkrankung, Myelomzellen, MM, Knochemark)
